$1.12
3.70% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US75382E1091
Symbol
RAPT
Sector
Industry

RAPT Therapeutics Inc Stock price

$1.12
-0.77 40.74% 1M
-3.06 73.21% 6M
-23.73 95.49% YTD
-12.71 91.90% 1Y
-31.62 96.58% 3Y
-28.35 96.20% 5Y
-11.88 91.38% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.04 3.70%
ISIN
US75382E1091
Symbol
RAPT
Sector
Industry

Key metrics

Market capitalization $39.15m
Enterprise Value $-53.64m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.53
P/B ratio (TTM) P/B ratio 0.41
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-114.85m
Free Cash Flow (TTM) Free Cash Flow $-100.80m
Cash position $97.91m
EPS (TTM) EPS $-2.78
P/E forward negative
Short interest 10.27%
Show more

Is RAPT Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

RAPT Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a RAPT Therapeutics Inc forecast:

1x Buy
13%
6x Hold
75%
1x Sell
13%

Analyst Opinions

8 Analysts have issued a RAPT Therapeutics Inc forecast:

Buy
13%
Hold
75%
Sell
13%

Financial data from RAPT Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 1.24 1.24
63% 63%
-
-1.24 -1.24
63% 63%
-
- Selling and Administrative Expenses 25 25
39% 39%
-
- Research and Development Expense 88 88
7% 7%
-
-114 -114
1% 1%
-
- Depreciation and Amortization 1.24 1.24
63% 63%
-
EBIT (Operating Income) EBIT -115 -115
3% 3%
-
Net Profit -107 -107
1% 1%
-

In millions USD.

Don't miss a Thing! We will send you all news about RAPT Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

RAPT Therapeutics Inc Stock News

Neutral
Seeking Alpha
4 months ago
Data from phase 2b study, using zelnecirnon for the treatment of patients with atopic dermatitis, is expected in Q3 of 2024; Potential for FDA clinical hold to be removed. The global atopic dermatitis market is expected to reach a valuation of $19.49 billion by the end of 2034. Preliminary ORR data established shows that tivumecirnon might ultimately be effective in treating CPI-naive NSCLC and...

Company Profile

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into allergically-inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Head office United States
CEO Brian Wong
Employees 131
Founded 2015
Website rapt.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today